{"componentChunkName":"component---gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/zh-Hant/hn/26690751","result":{"data":{"site":{"siteMetadata":{"title":"Reddit 热门","description":"用中文浏览Reddit热门内容","social":[{"name":"Twitter","url":"https://twitter.com/gatsbyjs","external":null,"prefetch":null},{"name":"GitHub","url":"https://github.com/gatsbyjs","external":null,"prefetch":null}],"menuLinks":[],"localize":[{"title":"Buzzing on Reddit","description":"See what's buzzing on Reddit in your native language","locale":"en","social":[{"name":"Reddit","url":"https://www.reddit.com/","external":true,"prefetch":null}],"menuLinks":[{"name":"Weekly Selection","url":"/issues","external":null,"prefetch":null},{"name":"RSS","url":"/rss.xml","external":null,"prefetch":false}]},{"title":"Reddit 熱門","description":"用中文瀏覽Reddit熱門內容","locale":"zh-Hant","social":null,"menuLinks":null}]}},"blogPost":{"__typename":"SocialMediaPost","id":"HnPost-26690751","excerpt":"","body":"","slug":"/hn/26690751","title":"New HIV vaccine with a 97% antibody response rate in phase I human trials","tags":["story","Hacker News"],"date":"April 04, 2021","dateISO":"2021-04-04T21:53:25.730Z","datetime":"2021-04-04 21:53","image":null,"imageAlt":null,"socialImage":null,"fields":{"basePath":"/"},"thirdPartyId":"26690751","provider":"Hacker News","url":"https://news.ycombinator.com/item?id=26690751","originalUrl":"https://www.europeanpharmaceuticalreview.com/news/141892/novel-hiv-vaccine-approach-shows-promise-in-landmark-first-in-human-trial/","imageRemote":"https://www.europeanpharmaceuticalreview.com/wp-content/uploads/HIV-Vaccine-1-scaled-e1612534046138.jpg","video":null,"channel":null,"channelUrl":null,"author":"MKais","authorUrl":"https://news.ycombinator.com/user?id=MKais","authorImage":null,"authorSlug":null,"score":161,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"__typename":"HnJson","localize":[{"title":"新型HIV疫苗I期人体试验抗体应答率达97%。","locale":"zh"},{"title":"新型HIV疫苗I期人體試驗抗體應答率達97%。","locale":"zh-Hant"},{"title":"抗体反応率97%の新規HIVワクチンをヒトでの第I相試験に投入","locale":"ja-JA"},{"title":"抗体反応率97%の新規HIVワクチンをヒトでの第I相試験に投入","locale":"ja"}]}},"previous":{"id":"HnPost-26688455","excerpt":"","slug":"/hn/26688455","title":"AMD's Zen 3 CPUs Are Susceptible to Spectre-Like Vulnerability","date":"April 04, 2021","__typename":"SocialMediaPost","parent":{"__typename":"HnJson","localize":[{"title":"AMD的Zen 3 CPU容易受到类似Spectre的漏洞影响。","locale":"zh"},{"title":"AMD的Zen 3 CPU容易受到類似Spectre的漏洞影響。","locale":"zh-Hant"},{"title":"AMDのZen 3 CPUにSpectreライクな脆弱性が存在する","locale":"ja-JA"},{"title":"AMDのZen 3 CPUにSpectreライクな脆弱性が存在する","locale":"ja"}]}},"next":{"id":"HnPost-26692144","excerpt":"","slug":"/hn/26692144","title":"Ubiquiti All but Confirms Breach Response Iniquity","__typename":"SocialMediaPost","date":"April 04, 2021","parent":{"__typename":"HnJson","localize":[{"title":"Ubiquiti全盘确认违规响应的不平等性","locale":"zh"},{"title":"Ubiquiti全盤確認違規響應的不平等性","locale":"zh-Hant"},{"title":"Ubiquiti、侵害対応を全面的に認める Iniquity","locale":"ja-JA"},{"title":"Ubiquiti、侵害対応を全面的に認める Iniquity","locale":"ja"}]}}},"pageContext":{"id":"HnPost-26690751","previousId":"HnPost-26688455","nextId":"HnPost-26692144","maxWidth":1024,"locale":"zh-Hant","hrefLang":"zh-Hant","originalPath":"/hn/26690751","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2506312863","2744905544","3493603132","3493603132","3513215887","386998304"]}